Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06715670 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06715670 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT06715670, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.
Interventions
- DRUG Zibotentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06715670
The ClinicalTrials.gov registry entry for NCT06715670 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zibotentan is the first listed.
NCT06715670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06715670 about?
NCT06715670 is a clinical study titled "A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants". This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.
What is the current status of trial NCT06715670?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-12-05. Estimated completion is 2025-02-28.
What interventions are being tested in trial NCT06715670?
The interventions under investigation include: Zibotentan (DRUG).
Who is sponsoring clinical trial NCT06715670?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.